Chiyoda Corporation
Chiyoda Global Headquarters
Minato Mirai Grand Central Tower
4-6-2, Minatomirai, Nishi-ku,
Yokohama 220-8765, Japan
www.chiyoda-corp.com/en

PRESS RELEASE

January 20, 2016

Chiyoda Awarded Advanced Pharmaceutical Plant to Manufacture Injection

Chiyoda Corporation ("Chiyoda") (TSE: 6366; ISIN: JP352800004) is pleased to announce that it has been awarded an EPC (Engineering, Procurement & Construction) contract by CMIC CMO ASHIKAGA Co., Ltd. (Headquartered in Ashikaga, Tochigi; Takeshi Mitani, Representative Director), a wholly owned company of CMIC HOLDINGS Co., Ltd. (Headquartered in Minato-ku, Tokyo; Kazuo Nakamura, Chairman & CEO), to construct the advanced pharmaceutical plant to manufacture injections.

1. Client: CMIC CMO ASHIKAGA Co., Ltd.
2. Project Name: EPC Work for advanced pharmaceutical plant to manufacture injections
3. Construction Site: Ashikaga city, Tochigi prefecture
4. Completion: March, 2018
5. Project Outline: This project is to construct a pharmaceutical plant to manufacture injection in compliance with PIC/S[*1] and three-regional (Japan, US and EU) GMP[*2] composed mainly of biological substances including high potent compounds and antibody drug. To enable such manufacturing, the plant has to secure high level of sterilization and highly efficient layout of classified space and facilities. The plant will be able to respond to the new anticancer drug field expected to expand significantly.

CMIC HOLDINGS Co., Ltd. promotes CMO (Contract Manufacturing Organization) related business to create added value through contract manufacturing services. By constructing advanced pharmaceutical plant, they will strengthen manufacturing activity in the injection field and expand their service to all kinds of pharmaceutical manufacturing including oral solid and semi-solid dosage.
Chiyoda believes its experience and know-how it has accumulated resulted in the award of the advanced plant. To meet the client's expectation, Chiyoda will make every effort to complete this world class plant successfully.

***1 PIC/S: Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme**)
***2 GMP stands for Good Manufacturing Practice which clarifies the rules and standards for drug manufacturers to comply with to secure the safety of pharmaceuticals and medical apparatus. It covers management for design, construction and operation of manufacturing plant and quality control for products. Ministerial orders by Ministry of Health, Labour and Welfare regulate the GMP in Japan.**

For more information, please contact:
Chiyoda Corporation
IR, PR & CSR Section
URL: http://www.chiyoda-corp.com/en